Synthesis and biological activities of aldose reductase inhibitors bearing acyl benzenesulfonamides as carboxylic acid surrogates

European Journal of Medicinal Chemistry

Volumn 33, Issue 1, 1998, Pages 15-22

  Donkor, Isaac O ^a   Abdel Ghany, Yasser S ^b   Kador, Peter F ^c   Mizoguchi, Tadashi ^c   Bartoszko Malik, Anita ^c   Miller, Duane D ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NATIONAL EYE INSTITUTE   (United States)

Author keywords

Acyl benzenesulfonamide; Aldose reductase inhibitor; Alrestatin; Carboxylic acid surrogate; Diabetic complication

Indexed keywords

ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; ALRESTATIN; ALRESTATIN DERIVATIVE; BENZENESULFONAMIDE DERIVATIVE; DRUG DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; DRUG ACTIVITY; DRUG SYNTHESIS; ENZYME ACTIVITY; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; THIN LAYER CHROMATOGRAPHY;

EID: 0031952440     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0223-5234(99)80071-3     Document Type: Article

References (24)

1. [1] Lipinski C.C., Hutson N.J., Ann. Rep. Med. Chem. 19 (1984) 169-177.
2. [2] Sarges R., Trends in Medicinal Chemistry, in: Mutschler E., Winterfeldt E. (Eds.). Proceedings of the 9th International Symposium on Medicinal Chemistry, VCH, Weinheim, Berlin, 1987, pp. 551-564.
3. [3] Sarges R., Prog. Med. Chem. 18 (1981) 191 -223.
4. [4] DCCT Research Group., New Engl. J. Med. 329 (1993) 683-689.
5. [5] Bristol J.A., Ann. Rep. Med. Chem. 28 (1992) 330.
6. [6] Mylari B.L., Larson E.R., Beyer T.A., Zembrowski W.J., Aldinger C.E., Dee M.F., Siegel T.W., Singleton D.H., J. Med. Chem. 34 (1991) 108-122.
7. [7] Hayman S., Kinoshita J.H., J. Biol. Chem. 240 (1965) 877-882.
8. [8] Kador P.F., Sharpless N.E., Mol. Pharmacol. 24 (1983) 521-531.
9. [9] Wilson D.K., Tarle I., Petrash J.M., Quiocho F.A., Proc. Natl. Acad. Sci. USA 90 (1993) 9847-951.
10. [10] Sarges R., Schnur R.C., Belletirre J.L., Peterson M.J., J. Med. Chem. 31 (1988) 230-243.
11. [11] Matassa V.G., Maduskuie T.P., Shapiro H.S., Hesp B., Snyder D.W., Aharoney D., Krell R.D., Keith R.A., J. Med. Chem 33 (1990) 1781-1790.
12. [12] Finkelstein H., Ber. 43 (1910) 1528.
13. [13] Dvornik D., An Approach to the Prevention of Diabetic Complications, in: Porte D. (Ed.), Aldose Reductase Inhibition, McGraw-Hill, New York, 1987, ch. 4.
14. [14] Cromlish J.A., Flynn G.T., J. Neurochem. 44 (1985) 1485-1493.
15. [15] Sato S., Kador P.F., Biochem. Pharmacol. 40 (1990) 1033-1042.
16. [16] Kador P.F., Kinoshita J.H., Sharpless N.E., J. Med. Chem. 28 (1985) 841-849.
17. [17] Kador P.F., Lee Y.S., Rodriguez L., Sato S., Bartoszko-Malik A., Abdel-Ghany Y.S., Miller D.D., Bioorg. Med. Chem. 3 (1995) 1313-1324.
18. [18] Harrison D.H., Bohren K.M., Ringe D., Petsko G.A., Gabbay K.H., Biochemistry 33 (1994) 2012-2020.
19. [19] Old S.E., Sato S., Kador P.F., Carper D., Proc. Natl. Acad. Sci. USA 87 (1990) 4942-4945.
20. [20] Morjana N., Flynn T.G., J. Biol. Chem. 264 (1989) 2906-2911.
21. [21] Morjana N., Lyons C., Flynn T.G., J. Biol. Chem. 264 (1989) 2912-2919.
22. [22] Smar M.W., Ares J.J., Nakayama T., Itabe H., Kador P.F., Miller D.D., J. Med. Chem. 35 (1992) 1117-1120.
23. [23] Whilney P.L., Folsch G., Nyman P.O., Malmastrom B.G., J. Biol. Chem. 242 (1967) 4206-4211.
24. [24] Jacobs W., Heidelberger M., J. Am. Chem. Soc. 39 (1917) 2418-2443.